Miscellaneous
124
Topics
194
Posts
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
-
659 - As per the PAAB Code section 1.8 Definitions, the New Healthcare Product is defined as follow: "Any prescription or non-prescription product manufactured and/or marketed in Canada by a particular company for a period of less than 2 years". It is our understanding that for any APS we are limited to one year of usage of the word "New" from initial marketing. However, please clarify, what is the less than two years period in the above statement for the “New Healthcare Product" is referring to?
-
-
-
-
606 - Hi! We would like to know what the role of PAAB is? Do you support innovation or the pharmaceuticals? This is not meant to be prejudiced in anyway. We've tried to work with pharmaceuticals to put a product that could eventually replace vaccines, replace the current international immunization plans, prevent outbreaks and epidemics.These are just starters. We've conducted full scale animal trials and safety trials and will soon be ready for Phase 1 trials for Universal Flu, HIV/AIDS, Cancer for leukemia and Hodgkin's, all enteric diseases and one to replace the immunization program. I see from PAAB's membership there are a lot of pharmaceutical and vaccine companies represented. We've approached several foundations, vaccine companies and pharmas and got similar "not interested" responses.
-
-
-
-
-
-
518 - Commercial employee asked a presenter AFTER presentation at a scientific conference why DRUG X has not been included in his presentation. DRUG X has not yet been approved by Health Canada but belongs to the employee's company pipeline. DRUG X efficacy/safety properties have not been discussed. Does this interaction constitutes off label promotion?
-
515 - We would like to ask PAAB regarding the interchangeability of the term “starter pack” used to identify a traditional sample pack. Certain products have starter packs specifically designed to initiate patients on treatment and help avoid dosing errors and contain patient educational materials. Our question is whether it is possible to refer to a simple sample pack as a “starter pack” when it is not specifically designed as a starter pack and is not mentioned in the TMA?
-
462 - Hi Patrick, We are planning a card that is for patients to carry with them, showing that they have been prescribed product X, which dose, physician contact info, etc (basically a wallet card). We are also preparing a stand for these cards that would sit in the physician's office. Each time they prescribe a patient product X, they grab a card from the stand and fill it out with the patient. The objective of the card is to instruct patients they need to show this card to other HCPs, to ensure these HCPs do not co-administer certain products with product X. Our question: can the card be submitted as patient-directed and the holder as physician-directed, as the holder will never leave the physician's office? The holder really is meant as instruction for the physician. Thank you.
-
-
449 - Hello, I am an international Arab candidate. I have been working for GlaxoSmithKline since 2008 in the sales and marketing field. I have plenty of contribution in communication and marketing, as I am planning to study for an advertising diploma in Canada. What will be the percentage for me to find a job in the medical advertising field after graduation? Thanks for your support.
-
442 - Hello there, I am a pharmacist from ON. I noticed some advertising from Mylan that I think is risky/dangerous and reckless in terms of the message it may be sending patients, the general public as well as pharmacists. I was wondering if I can make an anonymous complaint through this portal and in general what is the process for complaints? Details below. Mylan created a Fentanyl patch passport which is being distributed to patients who are dispensed Fentanyl by pharmacists. I have also seen it in airports on counters. The overall concept is good where they want patients to return their...
-
-
-
399 - We have an HCP-gated educational website/app containing endorsed medical education. We would like to post a program comprised of KOL-presented patient cases containing a video segment featuring one of that KOL's patients. What is the patient allowed to speak about on the video (e.g. their quality of life post-therapy...)?
-
